EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and
tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal
anti-VEGF injections. The study will be conducted in up to 30 centers in the United States
(US).